R. Christen

发表

In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.

S. Howell, F. Thiebaut, D. Shalinsky, 1993, The Journal of clinical investigation.

A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel

S. Aebi, T. Schnider, S. Howell, 1999, Cancer Chemotherapy and Pharmacology.

Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin.

S. Aebi, J. Wang, B. Cenni, 1997, Cancer research.

The role of DNA mismatch repair in platinum drug resistance.

S. Aebi, B. Cenni, D. Fink, 1996, Cancer research.

Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.

C. Macleod, S. Howell, D. C. Porter, 1990, The Journal of clinical investigation.

Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.

S. Howell, E. McClay, R. Christen, 1994, British Journal of Cancer.

Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.

S. Howell, E. McClay, R. Christen, 1993, Cancer research.

Evidence for a beneficial effect of plasma exchange in severe active lupus nephritis

G. Keusch, U. Binswanger, R. Christen, 1989 .

In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.

C. Macleod, S. Aebi, M. Haas, 1997, Cancer research.

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

J. Machiels, K. Korski, G. Meneses‐Lorente, 2022, Journal for ImmunoTherapy of Cancer.

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

T. Nayak, H. Verheul, D. Mahalingam, 2016, Oncotarget.

The Cisplatin-Induced Cellular Injury Response

S. Howell, G. Los, R. Christen, 1996 .

Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin.

S. Kirmani, S. Yen, D. Shalinsky, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progressive dilated cardiomyopathy in a patient with longstanding and complete prednisone-induced hematological remission of idiopathic hypereosinophilic syndrome

J. Schneider, J. Fehr, R. Jenni, 1989, Klinische Wochenschrift.

Enhancement of drug sensitivity of human malignancies by epidermal growth factor.

S. Howell, G. Los, R. Christen, 1995, British Journal of Cancer.

Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.

A. Eastman, S. Howell, F. Thiebaut, 1992, The Journal of clinical investigation.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

P. Paschka, G. Martinelli, W. Fiedler, 2016, Oncotarget.

Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin

B. Teicher, G. Bubley, S. Aebi, 1999, British Journal of Cancer.

all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells.

S. Aebi, B. Cenni, A. Sharma, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites.

S. Howell, E. McClay, R. Christen, 1997, Cancer research.

Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.

S. Howell, E. McClay, R. Christen, 1996, Cancer research.

Tamoxifen modulation of cisplatin cytotoxicity in human malignancies

S. Howell, E. McClay, R. Christen, 1993, International journal of cancer.

Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma a biologically important observation

S. Howell, R. Christen, K. Albright, 1993, Cancer.

Cyclosporin‐A therapy of pure red cell aplasia in a patient with B‐cell chronic lymphocytic leukemia

J. Fehr, R. Morant, R. Christen, 1989, European journal of haematology.

Fulminant group A streptococcal infections

K. Neftel, R. Christen, R. Moser, 1990, Klinische Wochenschrift.

Enhancement of the loss of multiple drug resistance by hydroxyurea.

S. Howell, D. Shalinsky, R. Christen, 1992, Seminars in oncology.

Observations on Control of N2 and N3 Neck Disease in Squamous Cell Carcinoma of the Head and Neck by Intra‐arterial Chemoradiation

S. Howell, S. Seagren, L. Orloff, 1998, The Laryngoscope.

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

J. Machiels, K. Korski, G. Meneses‐Lorente, 2020, Journal for ImmunoTherapy of Cancer.

Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages.

J. Blay, M. Toulmonde, A. Italiano, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

J. Blay, M. Toulmonde, A. Italiano, 2015, The Lancet. Oncology.

Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153.

S. Howell, A. Sharma, R. Christen, 1996, British Journal of Cancer.

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells

J. Wang, D. Fink, R. Christen, 1999, British Journal of Cancer.

Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents

G. Los, N. Onoda, R. Christen, 2001, Head & neck.

P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.

X. Lin, S. Howell, A. Kondo, 2001, Cancer research.

Mutagenic Effects of Cisplatin the Sensitivity of Human Colon Cancer Cells to the Cytotoxic p 53 Modulates the Effect of Loss of DNA Mismatch Repair on Updated

S. Howell, A. Kondo, R. Christen, 2001 .

Modulates the Effect of Loss of DNA Mismatch Repair on the Sensitivity of Human Colon Cancer Cells to the Cytotoxic and Mutagenic Effects of Cisplatin 1

S. Howell, A. Kondo, Xinjian Lin, 2001 .

Loss of DNA mismatch repair in acquired resistance to cisplatin.

C. Boland, S. Aebi, R. Fishel, 1996, Cancer research.

Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer.

S. Howell, S. Kirmani, L. Orloff, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.

S. Howell, D. Shalinsky, A. Jekunen, 1994, British Journal of Cancer.

Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells

X. Lin, P. Varadarajan, R. Christen, 2001, British Journal of Cancer.

Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.

J. Blay, M. Toulmonde, A. Italiano, 2020, European journal of cancer.

Signaling and drug sensitivity

Jeffrey A Jones, S. Howell, F. Thiebaut, 1994, Cancer and Metastasis Reviews.

Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues.

S. Aebi, D. Fink, R. Christen, 1997, British Journal of Cancer.

Identification of genes that mediate sensitivity to cisplatin.

X. Lin, S. Howell, A. Kondo, 2001, Molecular pharmacology.

Modulation of cisplatin resistance in human malignant melanoma cells.

A. Eastman, S. Howell, E. McClay, 1992, Cancer research.

Genes Whose Products Are Involved in the Recognition or Processing of cDDP DNA Adducts DNA

X. Lin, S. Howell, A. Kondo, 2001 .

Effect of c-Abl tyrosine kinase on the cellular response to paclitaxel-induced microtubule damage

X. Lin, B. L. Lee, R. Christen, 2000, British Journal of Cancer.

Cardiobacterium hominis endocarditis in a patient with a hypersensitivity reaction to penicillin. Successful treatment with partial resection of the posterior mitral valve leaflet and antibiotic therapy with cefazolin

R. Christen, 1990, Infection.

Phase I Trial of Retinoic Acid and cis-Platinum for Advanced Squamous Cell Cancer of the Head and Neck Based on Experimental Evidence of Drug Synergism

S. Howell, S. Kirmani, S. Seagren, 1996, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Regulation of initial vinblastine influx by P-glycoprotein.

S. Howell, D. Shalinsky, A. Jekunen, 1993, British Journal of Cancer.

Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel

S. Aebi, S. Howell, G. Los, 2000, Cancer Chemotherapy and Pharmacology.

Synergy between cisplatin and an inhibitor of S-adenosylmethionine dependent transmethylation in human ovarian adenocarcinoma cells.

S. Aebi, B. Cenni, P. Naredi, 1997, International journal of oncology.

p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection

R. Christen, M. Gerhold, M. Palmer, 2003, British Journal of Cancer.

Phase I trial of cisplatin in combination with glutathione.

S. Howell, S. Kirmani, P. Braly, 1994, Gynecologic oncology.

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

A. Lammertsma, G. V. van Dongen, M. Huisman, 2018, EJNMMI Research.

Phase I and pharmacokinetic study of intraperitoneal topotecan

Stephen B. Howell, S. Howell, P. Braly, 2004, Investigational New Drugs.

Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo.

R. Christen, J. Jones, D. Gately, 1994, British Journal of Cancer.